Ellagic Acid Induces in vitro Alkalinisation of the Digestive Vacuole in Drug-Sensitive Plasmodium falciparum Strain

Nur Hazirah Muchtar, Nik Nor Imam Nik Mat Zin, Fatin Sofia Mohamad, Nurhidanatasha Abu-Bakar
School of Health Sciences, Universiti Sains Malaysia, Kelantan, Malaysia

Submitted: 21 Apr 2021
Accepted: 25 Nov 2021
Online: 29 Aug 2022

To cite this article: Muchtar NH, Nik Mat Zin NNI, Mohamad FS, Abu-Bakar N. Ellagic acid induces in vitro alkalinisation of the digestive vacuole in drug-sensitive Plasmodium falciparum strain. Malays J Med Sci. 2022;29(4):43–52. https://doi.org/10.21315/mjms2022.29.4.5
To link to this article: https://doi.org/10.21315/mjms2022.29.4.5

Abstract

Background: Malaria is one of the leading causes of death worldwide caused by parasites of the genus Plasmodium. The reduced efficacy of the mainstay antimalarial drugs due to the widespread of drug-resistant Plasmodium falciparum (P. falciparum) necessitates an effort to develop novel antimalarial drugs with new targets. The effects of a phenolic compound, ellagic acid, against the malaria parasite have previously been reported. This present study aimed to evaluate the effect of ellagic acid on pH of the P. falciparum digestive vacuole.

Methods: The antimalarial potential of ellagic acid against the chloroquine-sensitive strain (3D7) of P. falciparum was assessed by using a malarial SYBR Green 1 fluorescence-based (MSF) assay. The effect of different concentrations of ellagic acid on the pH of the parasite’s digestive vacuole at mid-trophozoite stage was examined by using a ratiometric pH indicator, fluorescein isothiocyanate (FITC)-dextran on the flow cytometry.

Results: The result of the MSF assay showed that ellagic acid has an antimalarial activity (half-maximal inhibitory concentration [IC50] = 1.85 ± 4.57 nM) at par with a standard drug, artemisinin (IC50 = 1.91 ± 5.41 nM). The pH of the digestive vacuole of ellagic acid-treated parasites was significantly changed (pH values ranged from 6.11 to 6.74) in a concentration-dependent manner as compared to untreated parasites (P < 0.001). A similar effect was shown by the parasites treated with a standard proton pump inhibitor, concanamycin A.

Conclusion: These findings suggest that ellagic acid might have altered the digestive vacuole pH through the inhibition of proton pumps that regulate the acidification of this organelle. Overall, this study provides a valuable insight into the potential of ellagic acid as a promising antimalarial candidate with a novel mechanism of action.

Keywords: ellagic acid, phenolic compound, Plasmodium falciparum, pH, digestive vacuole, proton pump

Introduction

Malaria is a mosquito-borne disease that imposes significant health and socioeconomic impacts on humans. This disease contributes to the high rate of global infectious disease-related morbidity and mortality with 409,000 deaths from 229 million cases reported in 2019 (1). Out of the five Plasmodium species causing human malaria, Plasmodium falciparum (P. falciparum) is the most virulent and responsible for the highest disease burden, accounting for over 90% of the malaria deaths worldwide (1). Although a decline in the incidence of malaria results from the removal of mosquito breeding sites with insecticides, the use of long-lasting insecticide-treated nets and indoor residual spraying (2), an effective administration of antimalarial drugs can significantly reduce the overall malaria-related morbidity and mortality (3). The emergence of
Methods

The Malaria Parasite in vitro Culture

P. falciparum (3D7 strain) was maintained in RPMI 1640 medium (Gibco, USA) and type O+ human erythrocytes at 2% haematocrit by using an established protocol (39). Ring stage parasites (5% parasitemia) were synchronised by using 5% D-sorbitol (Sigma-Aldrich, USA) (29) as employed in the subsequent assay after 2 h post-synchronisation.

The Malarial SYBR Green 1 Fluorescence-Based Assay

The antimalarial activity of ellagic acid was determined by using the malarial SYBR Green 1 fluorescence-based (MSF) assay (40). The stock solution of ellagic acid (11 mM) (Sigma-Aldrich, USA) was diluted in RPMI 1640 medium at 10 concentrations of two-fold serial dilutions into 96-well microtiter plates. Artemisinin (Sigma-Aldrich, USA) was used as a standard drug, whereas infected erythrocytes without drug treatment served as a negative control. Aliquots (20 µL) of different concentrations of the compounds were transferred into other plates and added with suspensions (180 µL) of synchronised ring stage parasites (2% parasitemia, 2% haematocrit). After incubation for 48 h at 37 °C in a 5% CO₂, the cell suspensions in the plates were stained with 20× SYBR Green 1 solution (20 µL) (Sigma-Aldrich, USA) for 1 h at room temperature (41). The total fluorescence signal was measured with a microplate reader at the excitation and emission wavelengths of 490 nm and 530 nm, respectively and used to calculate the parasite inhibition (%) of each concentration. Half-maximal inhibitory concentration (IC₅₀) values of the drugs were determined by probit regression analysis with GraphPad Prism software version 8.

The FITC-Dextran Encapsulation into Erythrocytes

Packed erythrocytes were lysed in 2.25 volumes of ice-cold haemolysis buffer (5 mM sodium phosphate, pH 7.5) supplemented with Mg-ATP (1 mM) in the presence of fluorescein isothiocyanate (FITC)-dextran (25 µM) (Sigma-Aldrich, USA; 10 kDa) (27). After incubation for 10 min to allow the encapsulation of the
Ellagic acid induces the digestive vacuole alkalisation

The Digestive Vacuole pH Measurement

The pH calibration curve of FITC-dextran was generated to measure pH of the digestive vacuole (28, 42). Resealed erythrocytes containing FITC-dextran (2% haematocrit) were suspended in different buffers (20 mM) (MES, pH 4.0, 5.5 and 6.0; NaH₂PO₄, pH 6.5, 7.0, 7.5 and 8.0; TRIS, pH 9.0) supplemented with 150 mM NaCl and in the presence of 10 µM ionophore, carbonyl cyanide m-chlorophenylhydrazone (CCCP; Sigma-Aldrich, USA). FITC-dextran was excited by using a 488 nm argon ion laser of FACSCanto™ II flow cytometer (Becton Dickinson) and its fluorescence intensity was collected at FITC/green (525 nm) and phycoerythrin (PE)/yellow (585 nm) channels. The data were analysed using FCS Express 5 flow cytometry software (De Novo Software). The cell population was gated based on their side scatter (SSC) and forward scatter (FSC) profiles and an additional gate was established based on the fluorescence intensity of FITC-dextran at green and yellow. The peak of the fluorescence intensity (Rgy) for both green and yellow channels was obtained from the histograms from which the ratio of green/yellow Rgy was measured and plotted as a function of the pH.

Synchronised mid-trophozoite stage parasites (~34-h post-invasion) grown in resealed erythrocytes containing FITC-dextran (5% parasitemia, 2% haematocrit) were treated with ellagic acid at different concentrations based on the IC₅₀ value obtained: 0.93 nM (0.5 × IC₅₀), 1.85 nM (1.0 × IC₅₀) and 3.70 nM (2.0 × IC₅₀). A standard proton pump inhibitor, concanamycin A (75 nM) (Sigma-Aldrich, USA) was used as a positive control and untreated parasites as a negative control. After 4-h incubation, infected erythrocytes were selectively permeabilised with 0.035% saponin (Sigma-Aldrich, USA) to permeabilise the erythrocyte plasma membrane (EPM) and the parasitophorous vacuolar membrane (PVM), releasing FITC-dextran in the erythrocyte cytoplasm and allowing only FITC-dextran entrapped in the digestive vacuole for the digestive vacuole pH measurement (28, 36). Saponin-permeabilised parasites were washed twice in extracellular saline medium before measuring the FITC-dextran fluorescence intensity by using flow cytometry. Changes in pH of the digestive vacuole were measured by interpolating Rgy in the pH calibration curve of FITC-dextran.

Statistical Analysis

All experiments were conducted in triplicates (n = 3) on three independent occasions and analysed with GraphPad Prism software version 8. Mean values were expressed as mean (standard deviation [SD]). The data were tested for normality before proceeding to one-way analysis of variance (ANOVA), followed by Dunnett multiple comparisons at 95% confidence intervals (comparison between treated groups and control groups) using the IBM SPSS Statistics version 20. A P-value less than 0.05 was considered statistically significant.

Results

The MSF assay shows that ellagic acid exhibited an antimalarial activity (IC₅₀ = 1.85 ± 4.57 nM) against the 3D7 parasite at par with artemisinin (IC₅₀ = 1.91 ± 5.41 nM). The mid-trophozoite stage parasite-infected erythrocytes were then treated with three different concentrations of ellagic acid (0.93 nM, 1.85 nM and 3.70 nM) selected based on the IC₅₀ value previously obtained: 0.93 nM (0.5 × IC₅₀), 1.85 nM (1.0 × IC₅₀) and 3.70 nM (2.0 × IC₅₀). A standard proton pump inhibitor, concanamycin A (75 nM) (Sigma-Aldrich, USA) was used as a positive control and untreated parasites as a negative control. After 4-h incubation, infected erythrocytes were selectively permeabilised with 0.035% saponin (Sigma-Aldrich, USA) to probe into the cells, the isotonic condition of the erythrocytes was restored by using resealing buffer A before incubation with resealing buffer B for 20 min at 37 °C. Cell suspensions were washed twice with resealing buffer B and once with RPMI 1640 medium. Erythrocytes resealed with FITC-dextran in RPMI 1640 medium were used in the subsequent assay.
Figure 1. A standard pH calibration curve of FITC-dextran. A FITC-dextran pH calibration curve was constructed by suspending resealed erythrocytes in buffers of different pH (4.0–9.0) in the presence of an ionophore, carbonyl cyanide m-chlorophenylhydrazone (CCCP). The fluorescence intensity was collected at green and yellow channels by flow cytometry. The ratio of green/yellow fluorescence intensity ($R_{gy}$) was plotted on the y-axis against the pH on the x-axis. The dose-response curve was fitted by non-linear regression with GraphPad Prism ($R^2 = 0.9982$). The data are expressed as mean (SD) derived from three independent experiments done in triplicate.

Figure 2. Analysis of the pH of the digestive vacuole of *P. falciparum* after treatment with different concentrations of ellagic acid. (A) Representative scatter and fluorescence intensity profiles of the saponin-permeabilised parasite population at FITC/green and PE/yellow channels. (B) The effect of ellagic acid on pH of the digestive vacuole was investigated by using three different concentrations: $0.5 \times IC_{50}$ (0.93 nM), $1.0 \times IC_{50}$ (1.85 nM) and $2.0 \times IC_{50}$ (3.7 nM). The untreated mid trophozoite stage parasite was used as a negative control, while concanamycin A (CA; final concentration of 75 nM) was used as a positive control. The ratio ($R_{gy}$) was calculated for each treatment and converted to a pH value by means of the generated standard calibration curve in Figure 1.

Note: ***$P < 0.001$ was considered as statistically significant.
Prior to digestive vacuole pH measurement, the parasites were isolated with saponin to permeabilise the EPM and PVM, allowing only the digestive vacuole-located fluorescence intensity to be measured by the flow cytometer. Based on the established gating of saponin-permeabilised parasites (Figure 2A, left panel), the digestive vacuole pH values treated with 0.93 nM, 1.85 nM and 3.70 nM of ellagic acid resulted in 0.59, 0.91 and 1.22 pH unit higher, respectively than that of the untreated parasites (pH = 5.52 ± 0.38) (P < 0.001) (Figure 2B). The transition of the digestive vacuole pH from acidic to alkaline (pH = 7.35 ± 0.25) was also observed in the population of viable parasites treated with a standard proton inhibitor, concanamycin A.

Discussion

Ellagic acid has been shown to possess a number of biological and pharmacological activities (43–46). The compound exhibited a promising antimalarial activity in vitro, which is in agreement with a report by Garcia-Alvarez et al. (17) that ellagic acid was active against a wide range of P. falciparum strains with IC_{50} values in the nanomolar range. Notably, ellagic acid also has an in vivo antimalarial activity against P. vinckei petteri (17), P. berghei (47) and P. yoelli (15). The compound was found to be more active at mature stage parasites when most of the hemoglobin-rich host cell cytoplasm was ingested and digested (15). Artemisinin, the standard antimalarial drug showed an IC_{50} of 1.91 ± 5.41 nM that is consistent our previous studies (48–50), confirming the validity of the assay.

Only a few studies of the effect of ellagic acid on the malaria parasite's digestive vacuole are evident in the literature. Thus, the effect of ellagic acid with an emphasis on pH on the digestive vacuole was investigated to determine its possible mechanism of action. The present study reported an increase of the digestive vacuole pH following treatment with ellagic acid. Meanwhile, the digestive vacuole pH of untreated parasites was acidic, which is consistent with other studies using the same probe (27–28, 34). The treatment of the parasites with a V-type H^+-ATPase inhibitor, concanamycin A, resulted in the alkalinisation of the digestive vacuole. This suggests that the digestive vacuole proton pumps might be active in situ. This is in agreement with previous studies showing the capability of concanamycin A to disrupt pH regulation by preventing the transportation of H^+ into the digestive vacuole and out of the parasite across the parasite plasma membrane (51–52). Therefore, the inhibition of the proton pumps that causes the pH alteration of the digestive vacuole might become a possible mechanism of ellagic acid action.

Ellagic acid activity has also been linked to the inhibition of plasminogen II responsible for the digestion of haemoglobin and the impairment of β-haematin formation in the digestive vacuole (15–16, 26). The process of β-haematin formation could be inhibited by acting on heme monomers to coordinate their oxidation. Some phenolic compounds have exhibited the inhibitory effect on the heme polymerisation and β-haematin/hemozoin formation occurred particularly within the digestive vacuole. There is a possibility that ellagic acid might also have an effect on proton pumps located on the digestive vacuole's membrane, which results in the alteration of the acidic pH of this organelle. Hydroxychloroquine, a standard antimalarial drug has been shown to accumulate in the digestive vacuole along a pH gradient and inhibit the degradation of cargo derived from endocytosis or autophagy pathway. This process is executed by increasing the digestive vacuole pH, thus preventing the activity of the digestive vacuole enzymes (53).

The acidification of the parasite digestive vacuole is vital for the occurrence of various biological processes. It has been suggested that changes in the acidic environment might interfere with haemoglobin degradation and subsequently heme detoxification (48). This will inhibit the growth and proliferation of the parasite. Several studies described that the subtle pH changes in other acidic organelles, such as the lysosome caused the significant decrease in lysosomal enzyme activities, thus causing various pathological alterations (54–56). The increase of only a few tenths of a pH unit might have a major impact on the lysosomal function, whereas the organelle needs to maintain its acidic pH condition as in the digestive vacuole for the optimal activity of proteases (57). As the V-type H^+-ATPase is localised within a membrane-enclosed organelle, ellagic acid might probably disrupt the pumping function and therefore alter the digestive vacuole pH, which was evidenced in this study. The important role that the V-type H^+-ATPase plays in regulating the physiological pH of the digestive vacuole enables a primary explanation for the antimalarial potential of ellagic acid. Therefore, the postulated
mechanism of action of ellagic acid, which caused the pH alteration in the digestive vacuole is via the inhibition of the V-type H⁺-ATPase.

**Conclusion**

In summary, this in vitro study unveiled the promising antimalarial activity of ellagic acid against *P. falciparum* and the compound was shown at par with artemisinin. It is suggested that ellagic acid increased the digestive vacuole pH of the treated parasites probably by serving as an inhibitor of the proton pumps localised on the membrane of the digestive vacuole. A similar digestive vacuole pH alteration was shown by concanamycin A. This can be confirmed by performing isobologram analysis involving the interaction between ellagic acid and concanamycin A, the specific V-type H⁺-ATPase inhibitor or NaF, the specific V-type H⁺-pyrophosphatase inhibitor to confirm the target of ellagic acid.

**Acknowledgements**

We would like to acknowledge Dr. Khairul Mohd Fadzli Mustaffa and Encik Badrul Mat Zain from the Institute for Research in Molecular Medicine (INFORMM), Health Campus, Universiti Sains Malaysia for providing *P. falciparum* (3D7 strain) and access to the laboratory, equipment and cell culture facilities. We would also like to acknowledge the generous provision of the flow cytometry in the Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia.

**Conflict of Interest**

None.

**Funds**

The authors wish to thank the Ministry of Higher Education, Malaysia for providing the Fundamental Research Grant Scheme (FRGS) (FRGS/1/2019/STG03/USM/03/03).

**Authors’ Contributions**

Conception and design: NHM, NNINMZ, FSM, NAB

Analysis and interpretation of the data: NHM, NNINMZ, FSM

Drafting of the article: NHM, NNINMZ, FSM, NAB

Critical revision of the article for important intellectual content: NAB

Final approval of the article: NAB

Statistical expertise: NHM, NNINMZ, FSM, NAB

Obtaining of funding: NAB

Collection and assembly of data: NHM, NNINMZ, FSM, NAB

**Correspondence**

Dr Nurhidanatasha Abu-Bakar
MSc Parasitology (UKM), PhD Biochemistry (La Trobe University, Melbourne)
Lecturer and Researcher
(Biomedicine Programme)
School of Health Sciences,
Universiti Sains Malaysia,
16150 Kubang Kerian, Kelantan, Malaysia.
Tel: +609 767 7814
Fax: +609 767 7515
E-mails: natashaa@usm.my,
nettynab79@yahoo.com

**References**

1. World Health Organization (WHO). *World Malaria Report 2020* [Internet]. Geneva: World Health Organization; 2020. [Retrieved 2021 Jan 24]. https://www.who.int/publications/i/item/9789240015791

2. Tizifa TA, Kabaghe AN, McCann RS, van den Berg H, Van Vugt M, Phiri KS. Prevention efforts for malaria. *Curr Trop Med Rep*. 2018;5(1):41–50. https://doi.org/10.1007/s40475-018-0133-y

3. Kenangalem E, Poepoprodjo JR, Douglas NM, Burdam FH, Gdeumana K, Chalfein F, et al. Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: a longitudinal surveillance study. *PLoS Med.* 2019;16(5). https://doi.org/10.1371/journal.pmed.1002815
Ellagic acid induces the digestive vacuole alkalinisation

4. He Y, Campino S, Diez Benavente E, Warhurst DC, Beshir KB, Lubis I, et al. Artemisinin resistance-associated markers in Plasmodium falciparum parasites from the China-Myanmar border: predicted structural stability of K13 propeller variants detected in a low-prevalence area. *PLoS ONE*. 2019;14(3):e0213686. http://dx.plos.org/10.1371/journal.pone.0213686

5. Bekono BD, Nie-Kang F, Onguéné PA, Lifongo LL, Sippl W, Fester K, et al. The potential of anti-malarial compounds derived from African medicinal plants: a review of pharmacological evaluations from 2013 to 2019. *Malar J*. 2020;19(1):1–35. https://doi.org/10.1186/s12936-020-03231-7

6. Mina PR, Kumar Y, Verma AK, Khan F, Tandon S, Pal A, et al. Silymarin, a polyphenolic flavonoid impede *Plasmodium falciparum* growth through interaction with heme. *Nat Prod Res*. 2020;34(18):2647–2651. https://doi.org/10.1080/14786419.2018.1548449

7. Mamede L, Ledoux A, Jansen O, Frédéric M. Natural phenolic compounds and derivatives as potential antimalarial agents. *Planta Med.* 2020;86(9):585–618. https://doi.org/10.1055/a-1148-9000

8. Okello D, Kang Y. Exploring antimalarial herbal plants across communities in Uganda based on electronic data. *Evidence-based Complement Altern Med.* 2019;2019:1–27. https://doi.org/10.1155/2019/3057180

9. Burlacu E, Nisca A, Tanase C. A comprehensive review of phytochemistry and biological activities of *Quercus* species. *Forests*. 2020;11(9):1–24. https://doi.org/10.3390/F11090904

10. Usta C, Ozdemir S, Schiariti M, Puddu PE. The pharmacological use of ellagic acid-rich pomegranate fruit. *Int J Food Sci Nutr*. 2013;64(7):907–913. https://doi.org/10.3109/09637486.2013.798268

11. Tseng HC, Wu WT, Huang HS, Wu MC. Antimicrobial activities of various fractions of longan (Dimocarpus longan Lour. Fm Ke) seed extract. *Int J Food Sci Nutr*. 2014;65(5):589–593. https://doi.org/10.3109/09637486.2014.86181

12. Queiroz E de R, de Abreu CMP, Oliveira K da S, Ramos V de O, Fráguas RM. Bioactive phytochemicals and antioxidant activity in fresh and dried lychee fractions. *Rev Cienc Agron*. 2015;46(1):163–169. https://doi.org/10.1590/S1806-66902015000100019

13. Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R, Graziani G. Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. *Nutrients*. 2018;10(11):1–23. https://doi.org/10.3390/nu10111756

14. BenSaad LA, Kim KH, Quah CC, Kim WR, Shahimi M. Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A and B isolated from *Punica granatum*. *BMC Complement Altern Med.* 2017;17(1):1–10. http://dx.doi.org/10.1186/s12906-017-1555-0

15. Soh PN, Witkowski B, Olagnier D, Nicolau M-L, Garcia-Alvarez M-C, Berry A, et al. *In vitro* and *in vivo* properties of ellagic acid in malaria treatment. *Antimicrob Agents Chemother*. 2009;53(3):1100. http://www.ncbi.nlm.nih.gov/pubmed/19015354

16. Dell’Agli M, Galli GV., Corbett Y, Taramelli D, Lucantoni L, Habluetzel A, et al. Antiplasmodial activity of *Punica granatum* L. fruit rind. *J Ethnopharmacol*. 2009;125(2):279–285. https://doi.org/10.1016/j.jep.2009.06.025

17. Garcia-Alvarez MC, Moussa I, Njomnang Soh P, Nongonierma R, Abdoulaye A, Nicolau-Travers ML, et al. Both plants *Sebastiania chamaelea* from Niger and *Chrozophora senegalensis* from Senegal used in African traditional medicine in malaria treatment share a same active principle. *J Ethnopharmacol*. 2013;149(3):676–684. https://doi.org/10.1016/j.jep.2013.07.024

18. Alfaqih H, Abu-Bakar N. The potential of pyrogallol as a possible antimalarial drug candidate. *Acad J Microbiol Immun*. 2020;1(1). https://www.researchgate.net/publication/344624801

19. Tayel AA, El-Sedfy MA, Ibrahim AI, Moussa SH. Application of *Quercus infectoria* extract as a natural antimicrobial agent for chicken egg decontamination. *Rev Argent Microbiol*. 2018;50(4):391–397. https://doi.org/10.1016/j.ram.2017.12.003
20. Baharuddin NS, Abdullah H, Wan Abdul Wahab WNA. Anti-Candida activity of Quercus infectoria gall extracts against Candida species. J Pharm Bioallied Sci. 2015;7(1):15–20. https://doi.org/10.4103/0975-7406.148742

21. Abdullah AR, Hapidin H, Abdullah H. The role of semipurified fractions isolated from Quercus infectoria on bone metabolism by using hFOB 1.19 human fetal osteoblast cell model. Evidence-based Complement Altern Med. 2018;2018:5319528. https://doi.org/10.1155/2018/5319528

22. Kheirandish F, Delfan B, Mahmoudvand H, Moradi N, Ezatpour B, Ebrahimzadeh F, et al. Antileishmanial, antioxidant, and cytotoxic activities of Quercus infectoria Olivier extract. Biomed Pharmacother. 2016;82:208–215. https://www.ncbi.nlm.nih.gov/pubmed/27470357

23. Ozbilgin A, Durmuskahya C, Kilimecioglu AA, Kayalar H, Kurt O, Ermis VO, et al. In vitro efficacy of Quercus infectoria Oliv. and Achillea millefolium L. extracts against Blastocystis spp. isolates. Kafkas Univ Vet Fak Derg. 2013;19(3):511–516. https://doi.org/10.9775/kvfvd.2012.6196

24. Nik Mat Zin NNI, Mohamad MN, Roslan K, Sazeli AW, Moin NIA, Alias A, et al. In vitro antimalarial and toxicological activities of Quercus infectoria (Olivier) gall extracts. Malaysian J Med Sci. 2020;27(4):36–50. https://doi.org/10.21315/mjms2020.27.4.4

25. Nik Mat Zin NNI, Wan Mohd Rahimi WNA, Abu Bakar N. A review of Quercus infectoria (Olivier) galls as a resource for anti-parasitic agents: in vitro and in vivo studies. Malaysian J Med Sci. 2019;26(6):19–34. https://doi.org/10.21315/mjms2019.26.6.3

26. Sturm N, Hu Y, Zimmermann H, Fritz-Wolf K, Wittlin S, Rahlf S, et al. Compounds structurally related to ellagic acid show improved antiplasmodial activity. Antimicrob Agents Chemother. 2009;53(2):622–630. https://doi.org/10.1128/AAC.00544-08

27. Ibrahim N, Roslee A, Azlan M, Abu-Bakar N. Sub-lethal concentrations of artemisinin alter pH of the digestive vacuole of the malaria parasite, Plasmodium falciparum. Trop Biomed. 2020;37(1):1–14. https://www.ncbi.nlm.nih.gov/pubmed/33612713

28. Abu Bakar N. Measuring pH of the Plasmodium falciparum digestive vacuole by flow cytometry. Trop Biomed. 2015;32(3):485–493. https://www.ncbi.nlm.nih.gov/pubmed/26695209

29. Abu-Bakar N, Klonis N, Tilley L. Does artemisinin alter the pH of the malaria parasite digestive vacuole. Malaysian J Micro. 2013;9(1):112–116. https://www.researchgate.net/publication/334988239

30. Machin JM, Kantasadi AL, Vakonakis I. The complex of Plasmodium falciparum falcipain-2 protease with an (E)-chalcone-based inhibitor highlights a novel, small, molecule-binding site. Malar J. 2019;18(1):1–9. https://doi.org/10.1186/s12936-019-3043-0

31. Bedi RK, Patel C, Mishra V, Xiao H, Yada RY, Bhaumik P. Understanding the structural basis of substrate recognition by Plasmodium falciparum plasmepsin v to aid in the design of potent inhibitors. Sci Rep. 2016;6(4):1–17. https://doi.org/10.1038/srep31420

32. Wunderlich J, Rohrbach P, Dalton JP. The malaria digestive vacuole. Front Biosci - Sch. 2012;45(4):1424–1448. https://doi.org/10.2741/s344

33. Nasamu AS, Polino AJ, Istvan ES, Goldberg DE. Malaria parasite plasmepsins: More than just plain old degradative pepsins. J Biol Chem. 2020;295(25):8425–8441. https://doi.org/10.1074/jbc.REV120.009309

34. Hayward R, Saliba KJ, Kirk K. The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance. J Cell Sci. 2006;119(6):1016–1025. https://doi.org/10.1242/jcs.027975

35. Kapsinovik S, Leiserowitz L, Yang Y, Cloetens P, Pereiro E, Awamu Ndonglack F, et al. Biochemistry of malaria parasite infected red blood cells by X-ray microscopy. Sci Rep. 2017;7(1):1–10. https://doi.org/10.1038/s41598-017-00921-2

36. Saliba KJ, Allen RJW, Zissis S, Bray PG, Ward SA, Kirk K. Acidification of the malaria parasite's digestive vacuole by a H+-ATPase and a H+-pyrophosphatase. J Biol Chem. 2003;278(8):5605–5612. https://doi.org/10.1074/jbc.M208648200
37. Spillman NJ, Allen RJW, Kirk K. Na+ extrusion imposes an acid load on the intraerythrocytic malaria parasite. *Mol Biochem Parasitol.* 2013;186(1–2):1–4. https://doi.org/10.1016/j.molbiopara.2013.04.004

38. Tang T, Xu W, Ma J, Wang H, Cui Z, Jiang T, et al. Inhibitory mechanisms of DHA/CQ on pH and iron homeostasis of erythrocytic stage growth of *Plasmodium falciparum.* *Molecules.* 2019;24(10):1–17. https://doi.org/10.3390/molecules24101941

39. Pua JY, Abu Bakar N, Nik Kamarudin NAA, Ghazali SZ, Khairul MFM. Long cryopreserved lab-adapted *Plasmodium falciparum* increases resistance to chloroquine but not its susceptibility. *Life Sci Med Biomed* 2020;4(9). https://doi.org/10.28916/ljmb.4.9.2020.66

40. Mohd Zamri NH, Sinin NJ, Abu Bakar N. Preparation and in vitro characterization of resealed erythrocytes containing TMR-dextran for determination of haemoglobin uptake and transfer by the malaria parasite. *Int J Pharm.* 2019;524:19–24. Retrieved from https://journal.unisza.edu.my/ijmb/index.php/ijmb/article/view/250

41. Nik Mat Zin NNI, Omar Kathap M, Sul’ain MD, Abu Bakar N. Evaluation of antimalarial and toxicological activities of methanol and water leaves extracts of *Piper sarmentosum.* *Asian J Med Biomed.* 2019;12(1):10–17. https://doi.org/10.1055/s-0034-1368322

42. Ibrahim N, Abu-Bakar N. Measurement of pH of the digestive vacuole isolated from the *Plasmodium falciparum*-infected erythrocyte by digitonin permeabilization. *Int J Pharm Sci Res.* 2019;10(5):2587–2593. https://doi.org/10.13040/IJPSR.0975-8232.10(5).2587-93.

43. Aher AN, Pal SC, Yadav SK, Patil UK, Bhattacharya S. Antioxidant activity of isolated phytoconstituents from *Casuarina equisetifolia* Frost (Casuarinaceae). *J Plant Sci.* 2009;4(1):15–20. https://doi.org/10.3923/jps.2009.15.20

44. Bakkalbasi E, Mentes O, Artik N. Food ellagitannins-occurrence, effects of processing and storage. *Crit Rev Food Sci Nutr.* 2009;49(3):283–298. https://doi.org/10.1080/10408390802064404

45. Chao PC, Hsu CC, Yin MC. Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice. *Nutr Metab.* 2009;6:1–8. https://doi.org/10.1186/1743-7075-6-33

46. Martini S, D’Addario C, Colacevich A, Focardi S, Borghini F, Santucci A, et al. Antimicrobial activity against *Helicobacter pylori* strains and antioxidant properties of blackberry leaves (*Rubus ulmifolius*) and isolated compounds. *Int J Antimicrob Agents.* 2009;34(1):50–59. https://doi.org/10.1016/j.ijantimicag.2009.01.010

47. Muganga R, Angenot L, Tits M, Frédérick M. *In vitro* and *in vivo* antiplasmodial activity of three Rwandan medicinal plants and identification of their active compounds. *Planta Med.* 2014;80(6):482–489. https://doi.org/10.1055/s-0034-1368322

48. Mohd-Zamri NH, Mat-Desa NW, Abu Bakar N. Sensitivity of artesinin towards different stages of development of the malaria parasite, *Plasmodium falciparum.* *Trop Biomed.* 2017;34(4):759–769. https://www.ncbi.nlm.nih.gov/pubmed/33592945

49. Pinheiro LCS, Feitosa LM, da Silveira FF, Boechat N. Current antimalarial therapies and advances in the development of semi-synthetic artemisinin derivatives. *An Acad Bras Cienc.* 2018;90(1):1251–1271. https://doi.org/10.1590/0001-3765201820170830

50. Agarwal P, Anvikar AR, Pillai CR, Srivastava K. *In vitro* susceptibility of Indian *Plasmodium falciparum* isolates to different antimalarial drugs and antibiotics. *Indian Med Res.* 2017;146(5):622–628. https://doi.org/10.4103/ijmr.IJMR_1688_15

51. Pamarthy S, Kulshrestha A, Katara GK, Beaman KD. The curious case of vascular ATPase: Regulation of signaling pathways. *Mol Cancer.* 2018;17(1):1–9. https://doi.org/10.1186/s12943-018-0811-3

52. Chan CY, Prudom C, Raines SM, Charkhzarrin S, Melman SD, De Haro LP, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V; subunit a (Vph1p). *J Biol Chem.* 2012;287(13):10236–10250. https://doi.org/10.1074/jbc.M111.321133
53. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol.* 2020;16:155–166. https://doi.org/10.1038/s41584-020-0372-x

54. Colacurcio DJ, Nixon RA. Disorders of lysosomal acidification—The emerging role of V-ATPase in aging and neurodegenerative disease. *Ageing Res Rev.* 2016;32:75–88. https://doi.org/10.1016/j.arr.2016.05.004

55. Lee D, Hong JH. Nanoparticle-mediated therapeutic application for modulation of lysosomal ion channels and functions. *Pharmaceutics.* 2020;12(3):1–20. https://doi.org/10.3390/pharmaceutics12030217

56. Xu H, Ren D. Lysosomal physiology. *Annu Rev Physiol.* 2015;77:57–80. https://doi.org/10.1146/annurev-physiol-021014-071649

57. Eriksson I, Öllinger K, Appelqvist H. Analysis of lysosomal pH by flow cytometry using FITC-dextran loaded cells. *Methods Mol Biol.* 2017;1594:179–189. https://doi.org/10.1007/978-1-4939-6934-0_11